EUVIMEDEUVIMED entdecken
Crossref

Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature

Adrienne Conza iD, Racquel A Bitar iD, Fiona H Lynch iD, Pierre-Olivier Grenier, Elena B Hawryluk iD, Sarah E Servattalab iD

Pediatric Dermatology · 18.08.2026

DOI: 10.1111/pde.70337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Dermatology, online erschienen am 18.08.2026. Verfasst von Adrienne Conza und 5 weiteren Autor:innen. Beteiligte Einrichtung: UMass Chan Medical School, Worcester, Massachusetts, USA. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives This study aims to determine the level of hepatitis B virus (HBV) immunity in patients who had HBV serologic testing prior to starting immunomodulatory medication for dermatologic conditions at a single institution and to review evidence on waning immunity, serologic interpretation, and revaccination.

Methods

We performed a retrospective chart review of pediatric and young adult patients initiated on immunomodulatory therapy for dermatologic conditions who had HBV serologic testing prior to initiation. A focused literature review was conducted on durability of HBV immunity, HBV serologies in the context of immunomodulatory medications, and revaccination recommendations.

Results

In this cohort of 23 children, roughly 40% lacked HBV serologic immunity. Prior studies demonstrated that antibody‐mediated protection is heterogeneous and anti‐HBs titers decline over time. Existing guidelines are largely derived from adult populations. Evidence regarding revaccination strategies is mixed. Notably, absence of detectable anti‐HBs antibodies does not always equate to loss of immune memory or susceptibility to infection.

Conclusions

Anti‐HBs titers are variable and wane over time. Experts agree that patients should receive all recommended vaccinations before starting immunomodulatory therapy and be screened for HBV beforehand, based on adult guidelines. It is uncertain how well these recommendations apply to children, who generally have lower HBV risk and prevalence. Guidance is needed on how to manage pediatric patients without serologic evidence of HBV immunity before beginning biologic treatments.

Schlagwörter

Stichwörter der Autor:innen

childhepatitis B virusimmunosuppression therapyvaccination

Autor:innen und Institutionen

  • UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Division of Dermatology, Boston Children's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Adrienne Conza, Racquel A Bitar, Fiona H Lynch, Elena B Hawryluk, Sarah E Servattalab

Zitieren

APA

Conza, A., Bitar, R. A., Lynch, F. H., Grenier, P. O., Hawryluk, E. B., & Servattalab, S. E. (2026). Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature. Pediatric Dermatology. https://doi.org/10.1111/pde.70337

Vancouver

Conza A, Bitar RA, Lynch FH, Grenier PO, Hawryluk EB, Servattalab SE. Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature. Pediatric Dermatology. 2026. doi:10.1111/pde.70337

BibTeX
@article{Conza2026,
  author = {Conza, Adrienne and Bitar, Racquel A and Lynch, Fiona H and Grenier, Pierre-Olivier and Hawryluk, Elena B and Servattalab, Sarah E},
  title = {Hepatitis B Immunity in Children on Immunomodulators: Implications From a Pediatric Dermatology Cohort and Review of the Literature},
  journal = {Pediatric Dermatology},
  year = {2026},
  doi = {10.1111/pde.70337}
}
Kostenlos starten →